Vasoactive Drugs for Shock
Trial Summary
What is the purpose of this trial?
The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug for treating shock?
Research shows that norepinephrine is recommended as a first-line treatment for septic shock, and vasopressin can be effective when other drugs are not working. Combining norepinephrine with other drugs like phenylephrine or vasopressin has been studied in critically ill patients, suggesting potential benefits in managing shock.12345
How is the drug combination of Phenylephrine and Vasopressin unique for treating shock?
The combination of Phenylephrine and Vasopressin is unique for treating shock because they are both pure vasoconstrictors, meaning they work by narrowing blood vessels to increase blood pressure, unlike other treatments that may also affect heart function. This makes them particularly useful in cases where increasing vascular tone is the primary goal.26789
Research Team
John P Kress, MD
Principal Investigator
University of Chicago
Eligibility Criteria
This trial is for adults in the ICU with shock not improved by IV fluids, needing drugs through a central vein to manage blood pressure. It's not for those with severe right heart failure, cardiopulmonary arrest, or pregnant women.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive randomized vasoactive drug regimens to manage shock in the ICU
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Assessment of functional status and discharge outcomes
Treatment Details
Interventions
- Epinephrine
- Norepinephrine
- Phenylephrine
- Vasopressin
Phenylephrine is already approved in United States, European Union, Canada for the following indications:
- Nasal congestion
- Hypotension
- Burn injury management
- Nasal congestion
- Hypotension
- Burn injury management
- Nasal congestion
- Hypotension
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor